PLX190882
GSE127948: HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma
- Organsim human
- Type RNASEQ
- Target gene
- Project ARCHS4
Purpose: The clinical use of MEK inhibitors in uveal melanoma is limited by the rapid acquisition of resistance. The current study has used unbiased multi-omics and drug screens to identify the pan-HDAC inhibitor panobinostat as an effective strategy to limit MEK inhibitor resistance. SOURCE: Chia-Ho Cheng (chia-ho.cheng@moffitt.org) - Cancer Informatics Core Moffitt Cancer Center
View on GEOView in PlutoKey Features
Enhance your research with our curated data sets and powerful platform features. Pluto Bio makes it simple to find and use the data you need.
Learn MoreAnalyze and visualize data for this experiment
Use Pluto's intuitive interface to analyze and visualize data for this experiment. Pluto's platform is equipped with an API & SDKs, making it easy to integrate into your internal bioinformatics processes.
Read about post-pipeline analysisView QC data and experiment metadata
View quality control data and experiment metadata for this experiment.
Request import of other GEO data
Request imports from GEO or TCGA directly within Pluto Bio.
Chat with our Scientific Insights team